Your trusted source for investing success

Tag: NASDAQ

Himax Technologies, Inc. Declares Cash Dividend for FY2016

Himax Technologies (NASDAQ:HIMX) has declared a cash dividend of $.24 per ADS, equivalent to $0.12 per ordinary share for the year 2016.

As quoted in the press release:

The cash dividend will be payable on August 14, 2017 to all the shareholders of record as of July 31, 2017. The ADS book

BlackBerry Reports Profitability in Fiscal 2018 First Quarter

BlackBerry (NASDAQ:BBRY; TSX:BB) has announced financial results for the three months ended May 31, 2017.

As quoted in the press release:
Q1 Highlights

Q1 non-GAAP total revenue of $244 million; GAAP total revenue of $235 million
Q1 non-GAAP Company total software and services revenues of $169 million; GAAP Company total software and

CounterPath Announces Release of New Bria 5 Desktop for Windows and Mac

CounterPath (NASDAQ:CPAH; TSX:PATH) has announced it has released a new version of its Bria softphone for desktop that includes a number of new features and enhanced functionality.

As quoted in the press release:
Updates to Bria 5 for desktop include:

1080p high-definition video for much clearer image quality. Users will feel as

Brixton Metals To Acquire The Past-producing Hog Heaven Mine From Pan American Silver With Historical Estimate Of 47.3 Million Ounces Of Silver

Brixton Metals To Acquire The Past-producing Hog Heaven Mine From Pan American Silver With Historical Estimate Of 47.3 Million Ounces Of Silver

Brixton Metals Corporation (TSXV:BBB) (the “Company” or “Brixton”) is pleased to announce that it has entered into an asset purchase and sale agreement with Pan American Silver Corp. (PAAS: NASDAQ; PAAS: TSX) (“Pan American“), to acquire 100 percent interest in the Hog Heaven project, a past-producing silver mine (“Hog Heaven

DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals Receives Institutional Review Board Approval for Pivotal Phase 3 Clinical Trial of VAL-083 in Refractory GBM

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced it has received Institutional Review Board (IRB) approval to conduct its pivotal Phase 3 Study in Temozolomide-Avastin (bevacizumab) Recurrent GBM (STAR-3).

“IRB approval is an essential step in initiating patient enrollment in our

Enter Your Log In Credentials
×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network